Sichuan Biokin PharmaceuticalLtd Valuation
Is 688506 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 688506 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 688506's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 688506's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 688506?
Key metric: As 688506 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 688506's PE Ratio? | |
|---|---|
| PE Ratio | 21.4x |
| Earnings | CN¥3.80b |
| Market Cap | CN¥81.44b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 13.3x |
| Enterprise Value/EBITDA | 19.1x |
| PEG Ratio | -0.2x |
Price to Earnings Ratio vs Peers
How does 688506's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 25.7x | ||
688578 Shanghai Allist Pharmaceuticals | 19.7x | 18.4% | CN¥25.5b |
000999 China Resources Sanjiu Medical & Pharmaceutical | 17.2x | 11.2% | CN¥58.6b |
600085 Beijing Tongrentang | 33.2x | 15.8% | CN¥54.1b |
600196 Shanghai Fosun Pharmaceutical (Group) | 32.7x | 30.1% | CN¥62.1b |
688506 Sichuan Biokin PharmaceuticalLtd | 21.4x | -102.0% | CN¥81.4b |
Price-To-Earnings vs Peers: 688506 is good value based on its Price-To-Earnings Ratio (21.4x) compared to the peer average (25.7x).
Price to Earnings Ratio vs Industry
How does 688506's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?
| 0 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|
| 0 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: 688506 is good value based on its Price-To-Earnings Ratio (21.4x) compared to the CN Pharmaceuticals industry average (29.9x).
Price to Earnings Ratio vs Fair Ratio
What is 688506's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 21.4x |
| Fair PE Ratio | 4.9x |
Price-To-Earnings vs Fair Ratio: 688506 is expensive based on its Price-To-Earnings Ratio (21.4x) compared to the estimated Fair Price-To-Earnings Ratio (4.9x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | CN¥203.09 | CN¥226.42 +11.5% | 0.2% | CN¥226.83 | CN¥226.00 | n/a | 2 |
| Nov ’25 | CN¥186.31 | CN¥226.42 +21.5% | 0.2% | CN¥226.83 | CN¥226.00 | n/a | 2 |
| Oct ’25 | CN¥195.72 | CN¥226.42 +15.7% | 0.2% | CN¥226.83 | CN¥226.00 | n/a | 2 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Dong-E-E-JiaoLtd
CN¥36.7b
Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.
423
CN¥57.18
7D
-1.8%
1Y
13.3%
Jiangsu Kanion PharmaceuticalLtd
CN¥8.1b
Researches and develops, produces, and sells Chinese medicines.
600557
CN¥14.20
7D
-3.1%
1Y
-24.5%
Hunan Jiudian Pharmaceutical
CN¥11.8b
Researches, develops, produces, and sells pharmaceutical products in China and internationally.
300705
CN¥23.80
7D
-1.8%
1Y
12.8%